List of Excipients in API ENCORAFENIB
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing ENCORAFENIB
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Array BioPharma Inc | BRAFTOVI | encorafenib | 70255-025 | CELLULOSE, MICROCRYSTALLINE | 2033-08-05 |
| Array BioPharma Inc | BRAFTOVI | encorafenib | 70255-025 | COPOVIDONE K25-31 | 2033-08-05 |
| Array BioPharma Inc | BRAFTOVI | encorafenib | 70255-025 | CROSPOVIDONE | 2033-08-05 |
| Array BioPharma Inc | BRAFTOVI | encorafenib | 70255-025 | FERRIC OXIDE RED | 2033-08-05 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for ENCORAFENIB
Excipient focus: CELLULOSE, MICROCRYSTALLINE
ENCORAFENIB drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Array BioPharma Inc | encorafenib | 70255-025 |
| >Company | >Ingredient | >NDC |
ENCORAFENIB drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: COPOVIDONE K25-31
ENCORAFENIB drug variants containing COPOVIDONE K25-31
| Company | Ingredient | NDC |
|---|---|---|
| Array BioPharma Inc | encorafenib | 70255-025 |
| >Company | >Ingredient | >NDC |
ENCORAFENIB drug variants not containing COPOVIDONE K25-31
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSPOVIDONE
ENCORAFENIB drug variants containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Array BioPharma Inc | encorafenib | 70255-025 |
| >Company | >Ingredient | >NDC |
ENCORAFENIB drug variants not containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
ENCORAFENIB drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Array BioPharma Inc | encorafenib | 70255-025 |
| >Company | >Ingredient | >NDC |
ENCORAFENIB drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
ENCORAFENIB drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Array BioPharma Inc | encorafenib | 70255-025 |
| >Company | >Ingredient | >NDC |
ENCORAFENIB drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
ENCORAFENIB drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Array BioPharma Inc | encorafenib | 70255-025 |
| >Company | >Ingredient | >NDC |
ENCORAFENIB drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: GELATIN
ENCORAFENIB drug variants containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| Array BioPharma Inc | encorafenib | 70255-025 |
| >Company | >Ingredient | >NDC |
ENCORAFENIB drug variants not containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
ENCORAFENIB drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Array BioPharma Inc | encorafenib | 70255-025 |
| >Company | >Ingredient | >NDC |
ENCORAFENIB drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLOXAMER 188
ENCORAFENIB drug variants containing POLOXAMER 188
| Company | Ingredient | NDC |
|---|---|---|
| Array BioPharma Inc | encorafenib | 70255-025 |
| >Company | >Ingredient | >NDC |
ENCORAFENIB drug variants not containing POLOXAMER 188
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL
ENCORAFENIB drug variants containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Array BioPharma Inc | encorafenib | 70255-025 |
| >Company | >Ingredient | >NDC |
ENCORAFENIB drug variants not containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SHELLAC
ENCORAFENIB drug variants containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| Array BioPharma Inc | encorafenib | 70255-025 |
| >Company | >Ingredient | >NDC |
ENCORAFENIB drug variants not containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
ENCORAFENIB drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Array BioPharma Inc | encorafenib | 70255-025 |
| >Company | >Ingredient | >NDC |
ENCORAFENIB drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SUCCINIC ACID
ENCORAFENIB drug variants containing SUCCINIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Array BioPharma Inc | encorafenib | 70255-025 |
| >Company | >Ingredient | >NDC |
ENCORAFENIB drug variants not containing SUCCINIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
ENCORAFENIB drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Array BioPharma Inc | encorafenib | 70255-025 |
| >Company | >Ingredient | >NDC |
ENCORAFENIB drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch